A PHASE IIIB MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF A HIGHER DOSE OF OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS

  • STATUS
    Not Recruiting
Updated on 15 August 2022
multiple sclerosis
ocrelizumab

Summary

The purpose of this study is to compare the effects, good or bad, of a higher dose of ocrelizumab versus the approved dose of ocrelizumab on participants with PPMS. In this study, you will get either the approved dose or a higher dose of ocrelizumab. 

Description

A phase 3b study with about 699 participants

Details
Condition Radiologically Isolated Syndrome, MS, Multiple Sclerosis, Dermatite Atopique modérée ou grave
Clinical Study IdentifierTX264369
Last Modified on15 August 2022

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note